Xtandi has reached a key milestone: success in a Phase III trial eyeing the drug from Medivation and Astellas as a prechemo treatment for advanced prostate cancer.
A decade after obtaining the rights to the cancer drug selumetinib from Array Biopharma, the hungry pharma giant AstraZeneca is moving the MEK inhibitor into a late-stage study for non-small cell lung cancer. The move marks the opening of another front in AstraZeneca's offensive to rebuild a woefully inadequate late-stage pipeline.
U.K. contractor DrugDev has purchased software provider CFS Clinical with plans to merge the company's trial management program with its own investigator network.
Novella Clinical has snagged its first high-profile partnership since being bought by CRO giant Quintiles, teaming up with biotech Scioderm to manage a mid-stage trial of the company's rare skin disease treatment.
Faced with some serious safety issues, Ariad Pharmaceuticals today said it will shut down its pivotal EPIC 3 clinical study of Iclusig, putting the company under a dark cloud.
By David Grainger Clinical trial results are seldom reported in a form that is accessible to the public. To many people that is unacceptable for several reasons: it allows drug companies to...
One of the programs involved in AstraZeneca's $50 million bid to collaborate with Amgen on the development of a slate of biologics has run into a snafu of some sort. Late last summer investigators reported that a pair of mid-stage trials of AMG 181 for ulcerative colitis and Crohn's disease had been suspended, just after an early-stage trial was reported terminated.
Sanofi and Regeneron have rolled out promising Phase III data on their cholesterol drug alirocumab, which handily breezed by Merck's Zetia in lowering bad LDL cholesterol. The partners are in a high-stakes race to win the first regulatory approval for a PCSK9 inhibitor.
Coronado Biosciences' mid-stage trial of its experimental drug for Crohn's disease flopped in a mid-stage study. And while the biotech pointed to an unexpected placebo response and the possibility of finding something positive after some further analysis of the data, its stock cratered on the news, plunging 70%.
Parexel International has inked a deal to pool its clinical trial data management service with a Japanese provider, teaming up to expand its share of the local market.